Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors

NCT02038218 | Completed Phase 2 Results DMC

• 2 other identifiers: DTI-022R44CA125871-03
• Study Type: interventional
• Target: 29
• Locations: 1 country
• Sites: 3

Brief Summary

DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during a Phase I study. These findings support the preclinical responses seen in mice bearing intracerebrally implanted human breast and GBM tumor xenografts. Toxicity was acceptable - hyperbilirubinemia (in patients with liver disease and/or liver metastasis). No hematological, renal, cardiovascular, behavioral or cognitive impairment/neurotoxicities were noted during the Phase I human trial or in previous pre-clinical studies. The drug is available for use as a soy bean oil/egg yolk lecithin/glycerin water emulsion; the latter continues to be chemically and biologically stable and safe. Patients with advanced lung, breast and melanoma cancers spread to the CNS and primary CNS malignancies will be eligible for enrollment and treatment, providing the required blood and other eligibility requirements are met. The trial will be 2-tiered - patients with liver involvement vs. non-liver involvement will be treated with different doses of the drug. The trial is open and patients are currently being enrolled and treated with the protocol.

Conditions

Primary Brain Tumors; Metastatic Malignant Neoplasm to Brain

Keywords

DM-CHOC-PEN; CNS; brain; melanoma; lung cancer; breast cancer; glioblastoma multiforme; primary brain tumors

Outcome Measures

Primary Outcomes (2)

• Tumor Diameter

  Tumor Diameter from patient scans

  Until remission or off treatment due to progression

• Overall Survival

  Overall survival in months

  Until death

Study Arms (1)

DM-CHOC-PEN

EXPERIMENTAL

Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into: Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and; Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2. Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance.

Drug: 4-Demethyl-4-cholestryloxycarbonylpenclomedine

Interventions

4-Demethyl-4-cholestryloxycarbonylpenclomedine DRUG

This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement. Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient: Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and; Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2. Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance.

Also known as: DM-CHOC-PEN

DM-CHOC-PEN

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histological proof of a cancer - melanoma, breast, or lung cancer - which has spread to the CNS or glioblastoma (GBM) or other primary malignant neoplasm of the CNS which has been treated with standard treatments, which may include radiation, and must be measurable (RECIST).
• Patients must have life expectancy of at least 12 weeks and a Karnofsky performance score: \> 60 % (or a Zubrod performance status of \< 2).
• The age limit - 18 or older. Gender is not a criterion.
• All patients must be off previous chemo- and/or radiotherapy for at least three (3) weeks prior to entrance into the study and have recovered from any toxic effects induced by such treatment(s); no nitrosourea type drug or ipilumimab treatments are permitted within the last six (6) weeks prior to enrollment. No major surgery within 14 days of enrollment. Patients may continue to receive anti-estrogen/steroid therapy that has been initiated at least eight weeks prior to enrollment in the study.
• Patients should have adequate bone marrow function defined as a peripheral WBC \>3,000/mm3 with an ANC \>1500/mm3 and a platelet count \>100,000/mm3.
• Patients should have hepatic function (alkaline phosphatase, AST and ALT) \< ULN and renal functions with serum creatinine - \<1.5 x UNL. If a patient has liver metastasis and/or a history of liver disease - they will receive a lower dose of the drug per treatment protocol.
• Patients should not be allergic to eggs or soy beans. Patients must be medically, psychologically and neurologically stable and have triplicate baseline ECG's with a mean QTc interval \<500 ms and \>300 ms and neither a history of congenital prolonged or short QT syndrome. Patients with a history of cardiac disease must be stable.
• Patients must understand the nature of the study and be willing to sign an informed consent that complies with the investigator/DEKK-TEC policies and approved by the Human Investigation Review Committee. Patients must have CNS involvement - from a malignancy. Lung cancer may be either small cell or non-small cell.

You may not qualify if:

• Patients with concurrent severe and/or uncontrolled medical co-morbidities - including active infections, unstable uncontrolled diabetes, cardiovascular and pulmonary, renal, psychiatric or social conditions that could compromise the safety or compliance of treatment are not eligible.
• Concomitant chemotherapy or radiotherapy is not permitted.
• Pregnant or lactating females are excluded. Women of childbearing age, and their sexual partners, must use an effective contraception program. Males who are having sexual relations with women capable of child bearing must use the barrier birth control while on the study and for 3- months after the last dose of the study drug.
• Patients taking CYP3A4 inducers or inhibitors are not eligible since it is not known whether the study drug is metabolized through this pathway. The following CYP3A4 inhibitors/inducers are not permitted during the trial - the azole antifungal - fluconazole, erythromycin, phenobarbital, verapamil.
• Patients taking the following medications may experience QT/QTc interval prolongation and are not eligible for the trial - most anti-arrhythmia drugs (incl. amiodarone), erythromycin, quinolone antibiotics, ketoconazole, Zithromax, and phenothiazine and will be denied enrollment in the study. The possible interactions of these drugs and DM-CHOC-PEN have not been established. Patients receiving these drug will only be eligible if they discontinue the drugs and have an acceptable ECG.
• Coagulopathies - patients requiring full dose anticoagulation with warfarin are excluded, however, patients stable and on other anticoagulants can be included.

Sponsors & Collaborators

• DEKK-TEC, Inc.: lead
• Tulane University: collaborator
• Icahn School of Medicine at Mount Sinai: collaborator
• Detroit Clinical Research Center: collaborator
• National Cancer Institute (NCI): collaborator
• Ochsner Health System: collaborator
• The University of Texas Health Science Center, Houston: collaborator

Study Sites (3)

Tulane University Medical Center

New Orleans, Louisiana, 70112, United States

Location

Detroit Clinical Research Centers

Lansing, Michigan, 48336, United States

Location

The University of Texas Health Science Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Brain Neoplasms; Melanoma; Lung Neoplasms; Breast Neoplasms; Glioblastoma

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Skin Diseases; Skin and Connective Tissue Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Breast Diseases; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neoplasms, Glandular and Epithelial

Limitations and Caveats

The study was to evaluate the effects of DM-CHOC-PEN on brain tumor lesions. All patients had cancer involving the central or spinal NS; NSCLC responded best. However, most patients had cancer out side of the brain, which was the cause of death.

Results Point of Contact

• Title: Dr. Lee Roy Morgan
• Organization: DEKK-TEC, Inc.

lrm1579@aol.com

504-583-6135

Study Officials

• Lee R Morgan, MD, PhD

  DEKK-TEC, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2014
• First Posted: January 16, 2014
• Study Start: September 1, 2013
• Primary Completion: May 1, 2016
• Study Completion: August 1, 2020
• Last Updated: September 16, 2020
• Results First Posted: September 16, 2020

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: Five years
• Access Criteria: Per contact with the Study Director

Locations

US (3)